Difference between revisions of "Elotuzumab (Empliciti)"
Jump to navigation
Jump to search
m |
m (→References) |
||
| Line 24: | Line 24: | ||
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
| + | [[Category:Anti-CS1 antibodies]] | ||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
[[Category:Investigational]] | [[Category:Investigational]] | ||
Revision as of 17:54, 26 November 2014
General information
Class/mechanism: Monoclonal antibody that binds to CS1, a cell surface protein that is overly expressed on myeloma cells compared to normal cells.[1]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Preliminary data
Multiple myeloma
- Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, Kaufman JL, Leleu X, Tsao LC, Westland C, Singhal AK, Jagannath S. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012 Jun 1;30(16):1953-9. Epub 2012 Apr 30. PubMed
Patient drug information
No information available.
History of changes in FDA indication
- 5/19/2014: Granted FDA breakthrough designation "for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies."